ASX / MEDIA ANNOUNCEMENT

23 September 2014

DR MITCHELL GLASS DISCUSSES WITH BRR MEDIA THE UPDATE ON INVION's PHASE II STUDY OF INV102 (nadolol) IN ASTHMA PATIENTS

Clinical-stage drug development company Invion Limited (ASX:IVX) is delighted to invite investors to listen to Executive Vice President and Chief Medical Officer, Dr Mitchell Glass, as he provides further background to today's announcement regarding interim blinded data and progress of Invion's phase II clinical trial in patients with mild asthma. In this audiocast, Dr Glass discusses:

- What the interim blinded data from the phase II asthma trial has shown;
- The significance of safety signals in a clinical trial of a drug that is currently contraindicated in patients with chronic airway disease;
- Next steps in Invion's INV102 (nadolol) phase II clinical programs; and
- How emerging data is underpinning and supporting the development of nadolol as both an oral treatment for smoking cessation and an inhaled treatment for COPD and cystic fibrosis.

To access the audiocast, please visit this link: www.brrmedia.com/event/127115

FOR MORE INFORMATION CONTACT:
Managing Director and CEO
Dr Greg Collier
investor@inviongroup.com

MEDIA QUERIES:
Ben Walsh
Buchan Consulting
T: 02 9237 2800 or bwalsh@buchanwe.com.au

About INV102 (nadolol)
INV102 (nadolol) is a beta blocker (*beta adrenergic biased ligand*) currently used to treat high blood pressure and migraine that Invion is targeting as a therapy to treat chronic inflammatory airway disease including asthma, COPD and cystic fibrosis. Invion currently has two phase II clinical programs underway for oral nadolol – a 'smoking cessation' study assessing the effectiveness of INV102 in the smoking cessation of patients with COPD; and the 'NIMA' study of patients with mild asthma which is funded by the US National Institutes of Health. A collaboration with 3M Drug Delivery Systems is targeted to develop inhaled versions of this drug for asthma & COPD.

About Invion Limited
Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway. INV102 (nadolol), a beta blocker (*beta adrenergic biased ligand*) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). INV104 (zafirlukast) is a leukotriene receptor antagonist (*LTRA*) that reduces inflammation, constriction of the airways and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a *modified, naturally occurring human protein* which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX) with its clinical headquarters in Delaware, USA.